Windlas Biotech Ltd IPO- August 4, 2021

Windlas Biotech Ltd IPO- August 4, 2021

Company Background

Windlas Biotech was founded in the year 2001, the company provides pharmaceutical development services, large-scale manufacturing services and authentic yet affordable products to its customers and consumers around the world
 
Business Information

The company has 954 employees at their four state-of-the-art manufacturing facilities in Dehradun, Uttarakhand India. The company also have a sales force and distribution network spread across 14 states. The company market their own manufactured authentic nutraceutical, pharmaceutical and ayurvedic products to serve the semi-urban and rural communities at affordable prices. The registered name of the company is Windlas Biotech Limited (Formerly known as Windlas Biotech Private Limited).
 
Facts about the company
  • Service provider for end-to-end formulation development, licensing and commercial manufacturing of generic/branded generics including complex formulations in compliance with current GMP & regulatory requirements
  • Service provider for Product Registration to Distribution in ROW/Semi regulated/selective regulated markets
  • Strong Product Portfolio of First to launch in India products with DCGI clearance. Associated partner for more than 100 leading Domestic Pharmaceuticals/MNCs
  • Strong presence for anti-diabetic, cardiovascular, neuropsychiatry, respiratory health and nutraceuticals; gastroenterology, vitamins, minerals and supplements (“VMS”), analgesic, dermatological, cough/ cold etc.
  • 24×7 B2B support for formulation development, inventory & supply chain management, commercial manufacturing & distribution.
 
Points to note before investing in Windlas Biotech Ltd IPO
  • The company is the leading market player in the domestic pharmaceutical formulation CDMO segment.
  • It has a strong focus on the chronic therapeutic category.
  • The company has state-of-the-art manufacturing facilities in Dehradun, Uttarakhand.
  • Professional and experienced Promoters and a senior management team.
  • An innovative product portfolio of complex generic products.
  • Robust financial performance track record.
  • The company is approved for the handling of Controlled substances/narcotics
​
IPO Opening Date
August 4, 2021
IPO Closing Date
August 6, 2021
Issue Type
Book Built Issue IPO
Face Value
₹5 per equity share
IPO Price
448 to 460 per equity share
Market Lot
30 shares
Min Order Quantity
30 shares
Listing At
BSE, NSE
 
 Allotment, Listing and Refunds details
 
IPO Open Date
August 4, 2021
IPO Close Date
August 6, 2021
Basis of Allotment Date
August 11, 2021
Initiation of Refunds
August 12, 2021
Credit of Shares to Demat Account
August 13, 2021
IPO Listing Date
August 17, 2021
 
 
Know more-  www.5paisa.com/ipo
 
To apply from 5paisa Website- Apply IPO
 
To apply from 5paisa Mobile App- Apply IPO

We hope this information was helpful. For more details, you can post your queries below and we will be happy to share them with you.
 
Thank You!